L'istituto
Visite e Terapie
Alcat test
Ipertermia
      oncologica
Medical SPA
Newsletter
Pubblicazioni
Rassegna stampa
Calendario
Convenzioni
Partners
Siti Consigliati



Enhancement of the Efficacy of Chemotherapy with Oxaliplatin Plus 5-Fluorouracil by Pretreatment with IL-2 Subcutaneous Immunotherapy in Metastatic Colorectal Cancer Patients with Lymphocytopenia Prior to Therapy

P. LISSONI1,*, F. BRIVIO2, L. FUMAGALLI2, G. DI FEDE3 and G. BRERA4

Abstract
The present study was carried out to evaluate the influence of a short-period IL-2 administration on the efficacy of chemotherapy in metastatic colorectal cancer patients with pretreatment lymphocytopenia, which was defined as a lymphocyte count of less than 1500/mm3.

The study included 144 consecutive metastatic colorectal cancer patients, who underwent chemotherapy with oxaliplatin plus 5-fluorouracil. Lymphocytopenia was seen in 41/144 (28%) patients, who were randomized to receive chemotherapy alone or chemotherapy after a prechemoimmunotherapy with IL-2 (3 MIU twice/day for 3 consecutive days), whereas patients with a normal pretreatment lymphocyte count received only chemotherapy.

A normalization of the lymphocyte number was achieved in 12/19 lymphocytopenic patients pretreated with IL-2. The objective tumor regression rate achieved in patients with a normal lymphocyte count prior to chemotherapy was significantly higher compared to that obtained in lymphocytopenic patients treated with chemotherapy alone (54/103 vs. 3/22, p<0.01), whereas no significant difference occurred between patients with normal lymphocyte count and lymphocytopenic patients pretreated with IL-2 (54/103 vs. 8/19).

This study confirms that pretreatment lymphocytopenia is associated with reduced efficacy of chemotherapy in metastatic colorectal cancer patients. Moreover, it suggests that pretreatment with IL-2 before the onset of chemotherapy may enhance the efficacy of chemotherapy in lymphocytopenic patients. Therefore, the administration of IL-2 before the onset of chemotherapy to improve the immune status of cancer patients may be considered as a new chemoimmunotherapeutic combination, which may be recommended in the treatment of advanced cancer patients, particularly in those with cancer-related immune alterations.




Video correlati:

Sport e Alimentazione
intervista al prof. Fabrizio Angelini

Alcat Test Intervista al Dr Giuseppe di Fede

Disbiosi Intestinale

Articoli correlati:
- Alcat Home Page
- Definizione, cause e sintomi di intolleranza alimentare
- Intolleranze Alimentari
- Test diagnostici
- Test Alcat: strumenti, risultati e statistiche
- Pannelli test - pdf 442kb
- Guida al medico - pdf 409kb
- Guida al paziente - pdf 813kb
- Elenco laboratori per prelievo ALCAT test
- Elenco additivi
- Elenco coloranti
- Pagina FDA Kit ALCAT - pdf 24kb
- Pagina FDA Robocat II - pdf 23kb
- Pagina FDA Cell Science System - pdf 23kb
- Etichetta apparecchio Mylar 2008
News
- Articolo di dic. 2006
- Comprovata la scientificità e l'efficacia dell'Alcat Test
- L'efficacia dell'Alcat Test presentata in un convegno a Pavia
- Test per Intolleranze alimentari "ALCAT": un giudizio positivo
- ALCAT test: un valido strumento sia per la diagnosi che per la terapia delle intolleranze alimentari
Rassegna Stampa
- HOD 47 - gen '08 - il test di ALCAT per le intolleranze alimentari
- HOD 51 - gen '09 - test genetici per la ricerca dell'intolleranza al lattosio e glutine

Altri articoli
- Test ALCAT

- Migivapa: Antiox
- Coenzima Q10: un principio da riscoprire!

Torna su

Home | Lo Staff | Le Terapie | Medical SPA | Lavora con noi 
Pubblicazioni | Newsletter | Rassegna Stampa | Contatti | Come Raggiungerci
-

Istituto di Medicina Biologica Srl - Via Molino Delle Armi, 3 - 20123 Milano
tel. 02 58300445 (4 linee) - Fax 02 58300670

Sito realizzato da Aaron Ciancio